{"id":"https://openalex.org/W4310107091","doi":"https://doi.org/10.1182/blood-2022-157758","title":"Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis","display_name":"Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310107091","doi":"https://doi.org/10.1182/blood-2022-157758"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-157758","doi":"https://doi.org/10.1182/blood-2022-157758","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-157758","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037506454","display_name":"Kalatu Davies","orcid":"https://orcid.org/0000-0003-1850-3311","observed_orcids":["https://orcid.org/0000-0003-1850-3311"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kalatu R. Davies","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032767395","display_name":"Rajesh Kamalakar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajesh Kamalakar","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053461506","display_name":"Junhua Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Junhua Yu","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101590123","display_name":"Yinan Huang","orcid":"https://orcid.org/0000-0002-8909-0385","observed_orcids":["https://orcid.org/0000-0002-8909-0385"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]},{"id":"https://openalex.org/I44461941","display_name":"University of Houston","ror":"https://ror.org/048sx0r50","country_code":"US","type":"education","lineage":["https://openalex.org/I44461941"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yinan Huang","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL","2University of Houston, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]},{"raw_affiliation_string":"2University of Houston, Houston, TX","institution_ids":["https://openalex.org/I44461941"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007192173","display_name":"Anthony Wang","orcid":"https://orcid.org/0000-0002-9509-6257","observed_orcids":["https://orcid.org/0000-0002-9509-6257"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Wang","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043764554","display_name":"Kavita Sail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kavita Sail","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039095946","display_name":"Thomas Doerr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Doerr","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005802271","display_name":"Simon Sharmokh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Sharmokh","raw_affiliation_strings":["1AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063676674","display_name":"Alex Mutebi","orcid":"https://orcid.org/0000-0002-4433-5166","observed_orcids":["https://orcid.org/0000-0002-4433-5166"]},"institutions":[{"id":"https://openalex.org/I266595603","display_name":"Genmab (United States)","ror":"https://ror.org/05258cy55","country_code":"US","type":"company","lineage":["https://openalex.org/I266595603","https://openalex.org/I4210163256"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alex Mutebi","raw_affiliation_strings":["3Genmab, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Genmab, Princeton, NJ","institution_ids":["https://openalex.org/I266595603"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gilles Salles","raw_affiliation_strings":["4Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.3154,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.56167222,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":96},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"5058","last_page":"5059"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9369999766349792},{"id":"https://openalex.org/keywords/large-b-cell-lymphoma","display_name":"large B-cell lymphoma","score":0.9049999713897705},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.996999979019165},{"id":"https://openalex.org/keywords/primary-mediastinal-large-b-cell-lymphoma","display_name":"primary mediastinal B-cell lymphoma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/tisagenlecleucel","display_name":"tisagenlecleucel","score":0.9700000286102295},{"id":"https://openalex.org/keywords/axicabtagene-ciloleucel","display_name":"axicabtagene ciloleucel","score":1.0},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.972000002861023},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.9539999961853027},{"id":"https://openalex.org/keywords/length-of-hospital-stay","display_name":"length of hospital stay","score":0.7720000147819519},{"id":"https://openalex.org/keywords/bridging-therapy","display_name":"bridging therapy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.7620000243186951},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.6050000190734863}],"concepts":[{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6016868352890015},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5465375185012817},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5251217484474182},{"id":"https://openalex.org/C77088390","wikidata":"https://www.wikidata.org/wiki/Q8513","display_name":"Database","level":1,"score":0.33967316150665283},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3238193392753601},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26691746711730957},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.22914618253707886}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-157758","doi":"https://doi.org/10.1182/blood-2022-157758","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-157758","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283522419","https://openalex.org/W4220803898","https://openalex.org/W3092429248","https://openalex.org/W4415738217","https://openalex.org/W3097402257","https://openalex.org/W3097665172","https://openalex.org/W7127412664","https://openalex.org/W4405039623","https://openalex.org/W4311483339","https://openalex.org/W4310126175"],"abstract_inverted_index":{"Introduction:":[0],"Despite":[1],"its":[2],"association":[3],"with":[4,25,135,164,174,215,255,392,455,501,596],"promising":[5],"clinical":[6,130,527],"outcomes,":[7],"chimeric":[8],"antigen":[9],"receptor":[10],"T-cell":[11],"(CAR":[12],"T)":[13],"therapy":[14,42,78,91,118,171,224,318,381,513,568,602],"may":[15,514],"not":[16,50],"be":[17,515],"a":[18,84,393,402,456,465,516,525,588,604,621,627,632,639],"feasible":[19],"treatment":[20,250,371,517],"option":[21,518,653],"for":[22,212,277,388,646,654],"some":[23],"patients":[24,35,47,74,87,109,173,214,309,343,390,437,453,521,523,564,579,636],"relapsed":[26],"or":[27,166,187,259],"refractory":[28],"large":[29,176,190],"B-cell":[30,177,191],"lymphoma":[31,178,184,192,258,261],"(LBCL).":[32],"Although":[33],"more":[34,105,586],"have":[36],"been":[37],"referred":[38],"to":[39,53,80,127,158,274,358,373,483,535,582,608,613],"CAR":[40,81,95,116,136,169,221,248,316,328,359,374,379,415,476,502,511,560,566,600],"T":[41,82,96,117,137,170,222,249,317,329,360,375,380,416,434,477,503,512,561,567,601],"in":[43,60,172,300,337,353,384,451,546],"recent":[44],"years,":[45],"many":[46],"are":[48,617],"still":[49],"treated":[51],"due":[52],"anticipated":[54],"costs":[55,153,295,495,558],"and":[56,83,131,146,151,217,229,233,241,269,279,283,292,401,464,528,537,557,585,611,650],"logistical":[57],"challenges,":[58],"particularly":[59],"the":[61,129,180,247,338,354,430,488,532,552,583,597,609,635,644],"community":[62],"setting":[63,387],"(Gajra":[64],"et":[65,98,120],"al,":[66,99,121],"Immunotherapy":[67],"2020).":[68,103],"Because":[69],"of":[70,86,108,114,266,307,342,397,406,460,469,555,559,578,634],"long":[71],"manufacturing":[72],"times,":[73],"often":[75],"require":[76],"bridging":[77,90,368],"prior":[79,157,273,357,372,482,534],"subset":[85],"die":[88],"on":[89,569],"without":[92],"ever":[93],"receiving":[94,115,414],"(Chow":[97],"Am":[100],"J":[101],"Hematol":[102],"Furthermore,":[104],"than":[106,587],"one-half":[107],"relapse":[110,637],"within":[111,409,472,603,638],"1":[112],"year":[113],"(Spiegel":[119],"Blood":[122],"2021).":[123],"It":[124],"is":[125],"important":[126],"understand":[128],"economic":[132,529],"burden":[133],"associated":[134,500,595],"therapy.":[138,361,562],"We":[139],"assessed":[140],"health":[141,148,293,493],"care":[142,149,294,422,494],"resource":[143],"utilization":[144],"(HCRU)":[145],"all-cause":[147,492],"(medical":[150],"medication)":[152],"from":[154,271],"30":[155,355,452,480],"days":[156,161,245,356,400,432,463,474,481,485],"through":[159],"90":[160,244,410,431,473,484],"after":[162,246,475,486,538],"infusion":[163,223,376,536,539,610],"tisagenlecleucel":[165],"axicabtagene":[167],"ciloleucel":[168],"diffuse":[175],"(DLBCL),":[179],"most":[181,436],"common":[182],"non-Hodgkin":[183],"(NHL)":[185],"subtype,":[186],"primary":[188,553],"mediastinal":[189],"(PMBCL),":[193],"another":[194],"aggressive":[195],"NHL":[196],"subtype.":[197],"Methods:":[198],"This":[199],"observational,":[200],"retrospective":[201],"cohort":[202],"study":[203],"analyzed":[204],"MarketScan":[205],"(IBM,":[206],"Armonk,":[207],"NY)":[208],"administrative":[209],"claims":[210],"data":[211],"adult":[213],"DLBCL":[216],"PMBCL":[218],"who":[219,234,314],"received":[220,315,367,565],"between":[225],"October":[226],"1,":[227],"2017":[228],"March":[230],"31,":[231],"2021,":[232],"had":[235,346,420,440],"continuous":[236],"enrollment":[237],"6":[238],"months":[239,615],"before":[240],"at":[242,347,441],"least":[243,348,442],"date":[251],"(index":[252],"date).":[253],"Those":[254],"mantle":[256],"cell":[257],"follicular":[260],"were":[262,287,298,335,363,505,551,580],"excluded.":[263],"Hospital":[264],"length":[265],"stay":[267],"(LOS)":[268],"HCRU":[270,533,556],"30-days":[272],"90-days":[275],"post-infusion":[276,616],"inpatient":[278,386,448,549,571,592],"outpatient":[280,350,444,542],"hospital":[281,351,445,543],"visits":[282,286,352],"other":[284],"facility":[285],"examined.":[288],"All-cause":[289],"medical,":[290],"medication,":[291],"per":[296,496,624],"patient":[297],"reported":[299,364],"2021":[301],"US":[302],"dollars.":[303],"Results:":[304],"A":[305,340],"total":[306,491],"106":[308],"(DLBCL,":[310],"n=92;":[311],"PMBCL,":[312],"n=14)":[313],"(mean":[319],"age,":[320],"55":[321],"years;":[322],"men,":[323],"59%;":[324],"commercial":[325],"payer,":[326],"87%;":[327],"brand":[330],"information":[331],"available,":[332],"n=20":[333],"patients)":[334],"included":[336,540],"analysis.":[339],"majority":[341,633],"(78":[344],"[74%])":[345],"5":[349,443],"Many":[362],"as":[365,519],"having":[366],"and/or":[369],"lymphodepletion":[370],"(81":[377],"[76%]).":[378],"was":[382],"administered":[383],"an":[385,570,647],"92":[389],"(87%)":[391],"mean":[394,403,457,466,489],"(SD)":[395,404,458,467,490],"LOS":[396,459],"18.4":[398],"(11.3)":[399],"cost":[405,468],"$341,217":[407],"($245,564)":[408],"days.":[411],"Among":[412],"those":[413,499],"inpatient,":[417],"41":[418],"(45%)":[419],"intensive":[421],"unit":[423],"(ICU)":[424],"admissions":[425,449],"during":[426],"their":[427],"stay.":[428],"In":[429],"post-CAR":[433],"infusion,":[435,487],"(92":[438],"[87%])":[439],"visits.":[446,544],"Subsequent":[447],"occurred":[450],"(28%),":[454],"12":[461],"(12.44)":[462],"$83,952":[470],"($105,961)":[471],"infusion.":[478],"From":[479],"patient,":[497,625],"including":[498],"therapy,":[504],"$511,139":[506],"($293,631)":[507],"(Figure).":[508],"Conclusions:":[509],"While":[510],"LBCL":[520,655],"progress,":[522],"face":[524],"considerable":[526],"burden.":[530],"Both":[531],"frequent":[541],"Additionally,":[545],"this":[547],"analysis,":[548],"hospitalizations":[550],"driver":[554],"Most":[563],"basis,":[572],"requiring":[573],"prolonged":[574],"stays.":[575,593],"Nearly":[576],"half":[577,620],"admitted":[581],"ICU":[584],"quarter":[589],"experienced":[590],"secondary":[591],"Costs":[594],"logistically":[598],"challenging":[599],"month":[605],"leading":[606],"up":[607,612],"3":[614],"substantial,":[618],"averaging":[619],"million":[622],"dollars":[623],"indicating":[626],"significant":[628],"burden,":[629],"given":[630],"that":[631],"year.":[640],"These":[641],"findings":[642],"underscore":[643],"need":[645],"accessible,":[648],"off-the-shelf,":[649],"efficacious":[651],"therapeutic":[652],"patients.":[656],"Figure":[657],"1View":[658,661],"largeDownload":[659,662],"PPTFigure":[660],"PPT":[663],"Close":[664],"modal":[665]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2022-11-30T00:00:00"}